Raab & Moskowitz Asset Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.44M Sell
226,116
-6,128
-3% -$160K 1.1% 26
2026
Q1
$6.52M Sell
232,244
-8,720
-4% -$232K 1.45% 18
2025
Q4
$6M Sell
240,964
-39,910
-14% -$1.01M 1.31% 19
2025
Q3
$7.16M Sell
280,874
-3,230
-1% -$79.7K 1.6% 17
2025
Q2
$6.89M Sell
284,104
-7,953
-3% -$185K 1.64% 16
2025
Q1
$7.4M Buy
292,057
+6,490
+2% +$170K 1.86% 14
2024
Q4
$7.58M Buy
285,567
+26,433
+10% +$717K 1.86% 14
2024
Q3
$7.5M Buy
259,134
+20,197
+8% +$589K 1.9% 12
2024
Q2
$6.69M Buy
238,937
+82,497
+53% +$2.27M 1.82% 14
2024
Q1
$4.34M Buy
156,440
+22,693
+17% +$630K 1.21% 22
2023
Q4
$3.85M Buy
133,747
+1,884
+1% +$57K 1.22% 23
2023
Q3
$4.37M Buy
131,863
+5,325
+4% +$188K 1.54% 18
2023
Q2
$4.64M Sell
126,538
-1,096
-0.9% -$42.7K 1.59% 17
2023
Q1
$5.21M Sell
127,634
-700
-0.5% -$30.2K 1.9% 9
2022
Q4
$6.58M Buy
128,334
+2,131
+2% +$102K 2.5% 7
2022
Q3
$5.52M Sell
126,203
-7,124
-5% -$346K 2.32% 7
2022
Q2
$6.99M Buy
133,327
+1,312
+1% +$66.9K 2.74% 4
2022
Q1
$6.83M Sell
132,015
-3,797
-3% -$197K 2.34% 7
2021
Q4
$8.02M Sell
135,812
-1,426
-1% -$70.7K 2.63% 5
2021
Q3
$5.9M Sell
137,238
-685
-0.5% -$30.3K 2.13% 8
2021
Q2
$5.4M Sell
137,923
-815
-0.6% -$31.7K 1.98% 10
2021
Q1
$5.03M Sell
138,738
-249
-0.2% -$8.84K 1.96% 10
2020
Q4
$5.12M Sell
138,987
-8,562
-6% -$314K 2.1% 11
2020
Q3
$5.14M Sell
147,549
-4,774
-3% -$167K 2.37% 7
2020
Q2
$4.72M Buy
152,323
+584
+0.4% +$19.8K 2.29% 6
2020
Q1
$4.7M Buy
151,739
+6,979
+5% +$238K 2.56% 4
2019
Q4
$5.38M Buy
144,760
+1,336
+0.9% +$47.6K 2.13% 5
2019
Q3
$4.89M Sell
143,424
-250
-0.2% -$9.09K 2.14% 5
2019
Q2
$5.91M Buy
143,674
+4,317
+3% +$171K 2.62% 2
2019
Q1
$5.62M Sell
139,357
-593
-0.4% -$23.7K 2.57% 2
2018
Q4
$5.79M Sell
139,950
-8,046
-5% -$334K 2.85% 3
2018
Q3
$6.19M Buy
147,996
+3,761
+3% +$145K 2.57% 2
2018
Q2
$4.96M Sell
144,235
-5,484
-4% -$187K 2.37% 5
2018
Q1
$5.04M Sell
149,719
-1,668
-1% -$57.3K 2.48% 4
2017
Q4
$5.2M Sell
151,387
-4,211
-3% -$144K 2.51% 5
2017
Q3
$5.17M Sell
155,598
-2,801
-2% -$90K 2.5% 5
2017
Q2
$5.02M Buy
158,399
+706
+0.4% +$22.3K 2.5% 5
2017
Q1
$5.12M Sell
157,693
-1,020
-0.6% -$32.2K 2.67% 6
2016
Q4
$4.89M Sell
158,713
-221
-0.1% -$6.75K 2.65% 6
2016
Q3
$5.11M Sell
158,934
-4,115
-3% -$138K 2.88% 4
2016
Q2
$5.45M Sell
163,049
-5,549
-3% -$177K 3.1% 3
2016
Q1
$4.74M Sell
168,598
-939
-0.6% -$26.8K 2.82% 4
2015
Q4
$5.19M Buy
169,537
+1,627
+1% +$51.2K 3.09% 4
2015
Q3
$5M Sell
167,910
-517
-0.3% -$16.6K 3.23% 2
2015
Q2
$5.36M Buy
168,427
+5,143
+3% +$168K 3.3% 1
2015
Q1
$5.39M Sell
163,284
-7,734
-5% -$246K 3.27% 2
2014
Q4
$5.05M Sell
171,018
-54,243
-24% -$1.56M 2.89% 3
2014
Q3
$6.32M Buy
225,261
+7,613
+3% +$214K 3.07% 3
2014
Q2
$6.13M Buy
217,648
+38,905
+22% +$1.11M 2.92% 3
2014
Q1
$5.45M Sell
178,743
-27,389
-13% -$817K 3.01% 3
2013
Q4
$5.64M Buy
+206,132
New +$6M 3.24% 1

Other funds holding PFE

Raab & Moskowitz Asset Management's PFE Position: Q2 2026 in Review

Raab & Moskowitz Asset Management reduced its Pfizer (PFE) stake by 2.6% in Q2 2026, selling an estimated $160K and leaving 226,116 shares worth $5.44M. The position accounts for 1.1% of the portfolio, ranked #26.

Raab & Moskowitz Asset Management first reported a position in PFE in Q4 2013 and has held it in 51 quarters since. The position peaked at $8.02M in Q4 2021. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Raab & Moskowitz Asset Management held 226,116 shares of Pfizer worth $5.44M as of Q2 2026.
  • Raab & Moskowitz Asset Management sold 6,128 Pfizer shares in Q2 2026, an estimated $160K.
  • Pfizer made up 1.1% of Raab & Moskowitz Asset Management's portfolio in Q2 2026, its #26 holding.
  • Raab & Moskowitz Asset Management first reported a position in Pfizer in Q4 2013 and has held it in 51 quarters since.
  • Raab & Moskowitz Asset Management's Pfizer position peaked at $8.02M in Q4 2021.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Raab & Moskowitz Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.